Header1.jpg

About us: Overview

PIONEERING A NEW WAY FORWARD IN INFERTILITY TREATMENT

Igyxos Biotherapeutics, a French biotechnology company, is dedicated to addressing the growing global need for improved infertility solutions through novel therapeutics that make treatment more effective and efficient for men and women. To transform infertility treatment and enhance patients’ outcomes, we’re pioneering the first monoclonal antibody (mAb)-based treatment that binds to and enhances the activity of gonadotropins – hormones involved in reproduction – and significantly improves their activity for infertility treatments.

Igyxos’ unique scientific approach offers the bold potential to overcome the limitations that have limited the success rates of current infertility treatments.

SINGULAR FOCUS ON INFERTILITY

Igyxos brings together a world-renowned team with deep and proven experience in fertility research and monoclonal antibody therapeutics. This specialized combination of expertise makes us stand apart in the field of infertility treatment. Dr. Marie-Christine Maurel, founder and chief scientific officer, discovered our lead antibody class during her work at RetroPharm, a company dedicated to improving animal health. Through extensive experimentation, Dr. Maurel demonstrated that these anti-Follicle Stimulating Hormone (FSH) antibodies bind to FSH, leading to conformational changes that significantly improve receptor binding and FSH activity. Igyxos was spun out of RetroPharm in 2017 to develop this new class of infertility treatment for humans.

 

Igyxos has successfully raised Series A funding to support the advancement of our clinical development program. Investors include BPI France, Go Capital, and UI Investissement.

Identifying mAbs that significantly improve FSH receptor binding and activity.

We are developing IGX12 as a first-in-class mAb therapeutic, designed to boost the bioactivity of Follicle Stimulating Hormone (FSH), a key hormone associated with the development of eggs in women and sperm in men.